Loading...
XSHG
600216
Market cap1.91bUSD
Dec 05, Last price  
14.02CNY
1D
0.65%
1Q
-8.13%
Jan 2017
10.57%
Name

Zhejiang Medicine Co Ltd

Chart & Performance

D1W1MN
XSHG:600216 chart
P/E
11.62
P/S
1.44
EPS
1.21
Div Yield, %
1.07%
Shrs. gr., 5y
0.02%
Rev. gr., 5y
5.88%
Revenues
9.38b
+20.29%
1,884,658,7272,196,496,6402,208,825,5913,761,029,3284,183,740,7744,558,265,1734,825,968,3785,264,006,1164,932,920,2364,832,291,8324,496,662,3785,279,204,0315,692,580,3656,858,741,5807,043,927,6187,326,934,7999,129,094,4968,115,804,6487,794,145,9719,375,216,922
Net income
1.16b
+170.11%
81,643,17060,618,55656,604,978972,627,3141,213,754,8251,144,708,6941,012,476,289848,542,502452,095,249169,739,354161,801,304450,102,013253,145,602364,549,966342,772,695717,399,5641,045,322,100362,613,741429,639,6261,160,510,670
CFO
1.22b
+92.85%
25,143,347169,506,018227,672,9671,199,977,1811,465,089,3911,316,312,173912,753,822807,488,234655,086,217549,899,398106,539,172336,135,774503,468,945579,907,748447,249,2871,256,721,9801,136,655,957520,603,490634,311,1631,223,298,641
Dividend
Jul 10, 20240.15 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Zhejiang Medicine Co., Ltd. produces and sells life nutrition and pharmaceutical products in China. The company offers life nutrition products, such as synthetic vitamin E, vitamin A, natural vitamin E, vitamin H, vitamin D3, coenzyme Q10, carotene, cantharidin, lutein, lycopene, and other vitamins and vitamin products. It also provides pharmaceutical manufacturing products, including anti-drug resistant antibiotics, anti-malaria and other pharmaceutical raw materials, quinolones, and anti-drug resistant products; and pharmaceutical products comprising sugars and hormones. The company was founded in 1997 and is headquartered in Shaoxing, China.
URL
https://www.zmc.top/
IPO date
Oct 21, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT